Hussman Strategic Advisors’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-4,200
| Closed | -$729K | – | 292 |
|
|
2025
Q4 | $729K | Buy |
+4,200
| New | +$765K | 0.18% | 211 |
|
|
2023
Q3 | – | Sell |
-12,400
| Closed | -$1.74M | – | 308 |
|
|
2023
Q2 | $1.74M | Sell |
12,400
-8,200
| -40% | -$1.13M | 0.32% | 142 |
|
|
2023
Q1 | $2.91M | Hold |
20,600
| – | – | 0.46% | 79 |
|
|
2022
Q4 | $3.22M | Sell |
20,600
-5,400
| -21% | -$776K | 0.52% | 69 |
|
|
2022
Q3 | $3.19M | Hold |
26,000
| – | – | 0.55% | 51 |
|
|
2022
Q2 | $3.46M | Hold |
26,000
| – | – | 0.6% | 41 |
|
|
2022
Q1 | $3.56M | Buy |
26,000
+5,200
| +25% | +$725K | 0.69% | 26 |
|
|
2021
Q4 | $3.6M | Buy |
20,800
+2,200
| +12% | +$335K | 0.79% | 14 |
|
|
2021
Q3 | $2.7M | Hold |
18,600
| – | – | 0.6% | 39 |
|
|
2021
Q2 | $2.46M | Buy |
18,600
+8,300
| +81% | +$1.09M | 0.51% | 61 |
|
|
2021
Q1 | $1.32M | Buy |
+10,300
| New | +$1.27M | 0.27% | 143 |
|
|
2020
Q2 | – | Sell |
-30,000
| Closed | -$2.41M | – | 276 |
|
|
2020
Q1 | $2.41M | Buy |
+30,000
| New | +$3.11M | 0.65% | 33 |
|
|
2019
Q2 | – | Sell |
-800
| Closed | -$72K | – | 197 |
|
|
2019
Q1 | $72K | Hold |
800
| – | – | 0.02% | 207 |
|
|
2018
Q4 | $67K | Buy |
800
+300
| +60% | +$28.1K | 0.02% | 217 |
|
|
2018
Q3 | $54K | Hold |
500
| – | – | 0.02% | 199 |
|
|
2018
Q2 | $55K | Sell |
500
-200
| -29% | -$20.8K | 0.01% | 202 |
|
|
2018
Q1 | $70K | Sell |
700
-50,000
| -99% | -$5.12M | 0.02% | 176 |
|
|
2017
Q4 | $4.99M | Buy |
50,700
+700
| +1% | +$66.4K | 1.43% | 13 |
|
|
2017
Q3 | $4.68M | Sell |
50,000
-25,000
| -33% | -$2.65M | 1.13% | 24 |
|
|
2017
Q2 | $8.34M | Hold |
75,000
| – | – | 1.85% | 4 |
|
|
2017
Q1 | $7.36M | Sell |
75,000
-25,000
| -25% | -$2.38M | 1.63% | 7 |
|
|
2016
Q4 | $9.19M | Buy |
100,000
+23,500
| +31% | +$2.03M | 1.83% | 4 |
|
|
2016
Q3 | $6.47M | Buy |
76,500
+74,500
| +3,725% | +$6.26M | 1.07% | 40 |
|
|
2016
Q2 | $163K | Hold |
2,000
| – | – | 0.02% | 109 |
|
|
2016
Q1 | $143K | Hold |
2,000
| – | – | 0.02% | 136 |
|
|
2015
Q4 | $142K | Sell |
2,000
-125,000
| -98% | -$8.4M | 0.02% | 145 |
|
|
2015
Q3 | $7.81M | Sell |
127,000
-73,000
| -37% | -$5.1M | 0.99% | 33 |
|
|
2015
Q2 | $14.5M | Sell |
200,000
-20,000
| -9% | -$1.48M | 1.68% | 6 |
|
|
2015
Q1 | $16.9M | Buy |
220,000
+20,000
| +10% | +$1.43M | 1.77% | 5 |
|
|
2014
Q4 | $13.4M | Buy |
+200,000
| New | +$12.6M | 1.33% | 15 |
|
Other funds holding DGX
VCM
VPM
EIG
Hussman Strategic Advisors's DGX Position: Q1 2026 in Review
Hussman Strategic Advisors sold out of Quest Diagnostics (DGX) in Q1 2026, closing a stake of 4,200 shares — an estimated $729K sold.
Hussman Strategic Advisors first reported a position in DGX in Q4 2014 and held it in 30 quarters. The position peaked at $16.9M in Q1 2015. 1,064 funds tracked by Wall St. Rank hold DGX as of Q1 2026.
- Hussman Strategic Advisors reported no remaining Quest Diagnostics position as of Q1 2026 after selling out during the quarter.
- Hussman Strategic Advisors sold 4,200 Quest Diagnostics shares in Q1 2026, an estimated $729K.
- Hussman Strategic Advisors first reported a position in Quest Diagnostics in Q4 2014 and held it in 30 quarters.
- Hussman Strategic Advisors's Quest Diagnostics position peaked at $16.9M in Q1 2015.
- 1,064 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.
Based on Hussman Strategic Advisors's 13F filing for Q1 2026, filed 11 May 2026.